Abstract

The standard radiotherapy (RT) fractionation practiced in India and worldwide is 50 Gy in 25 fractions over 5 weeks to the chest wall or whole breast followed by tumour bed boost in case of breast conservation (BCS). A body of validated data exists regarding hypofractionation in breast cancer. We here report initial results for 135 patients treated at our center with the START-B type of fractionation. From May 2011 till July 2012, women with all stages of breast cancer (excluding metastatic), who had undergone BCS or mastectomy were planned for 40 Gy in 15 fractions over 3 weeks to chest wall/whole breast and supraclavicular fossa (where indicated) followed by tumour bed boost in BCS patients. Planning was done using Casebow's technique. The primary end point was to assess the acute toxicity and the cosmetic outcomes. Using cosmetic scales; patients were assessed during radiotherapy and at subsequent follow up visits with the radiation oncologist. Of the 135 patients, 62 had undergone BCS and 73 mastectomy. Median age of the population was 52 years. Some 80% were T1 and T2 tumours in BCS whereas most patients in mastectomy group were T3 and T4 tumours (60%). 45% were node negative in BCS group whilst it was 23% in the mastectomy group. Average NPI scores were 3.9 and 4.9, respectively. Most frequently reported histopathology report was infiltrating ductal carcinoma (87%), grade III being most common (58%), and 69% were ER positive tumours, and 30% were Her 2 Neu positive. Triple negative tumours accounted for 13% and their mean age was young (43 yrs.) The maximum acute skin toxicity at the end of treatment was Grade 1 in 94% of the mastectomy group patients and 71% in BCS patients. Grade 2 toxicity was 6% in mast group and 23% in BCS group. Grade 3 was 6% in BCS group, no grade 3 toxicity in mastectomy patients and there was no grade 4 skin toxicity in any case. Post RT at 1 month; 39% of BCS patients had persisting Grade I skin reaction which was only 2% in mastectomy patients. At 3 months post RT, 18% patients had persisting hyperpigmentation. At 6 months 8% patients had persisting erythema in the BCS group only. Some 3% BCS and 8% mastectomy patients had lymph edema till the date of evaluation. Cosmetic outcome in BCS patients remained good to excellent 6 months post surgery and radiotherapy. 1 patient of BCS and 3 patients of mast had developed metastatic disease at the time of evaluation. Hypofractionated RT is well tolerated in Indian population with reduced acute skin toxicity and good cosmetic outcome. Regimens such as these should be encouraged in other centers to increase machine output time. The study is on-going to assess long term results.

Highlights

  • Breast cancer (ICD 10: C50) is the second most common cancer among both sexes worldwide (Globocon, 2012)

  • The standard radiotherapy (RT) fractionation in breast cancers practised in India and worldwide is 50Gy in 25 fractions over 5 weeks to the chest wall or whole breast followed by tumour bed boost in case of breast conservation (BCS)

  • Triple negative tumours accounted for 13% and their mean age was younger than the general population (43 yrs.) The maximum acute skin toxicity at the end of treatment was Grade 1 in 94% of the mastectomy group of patients and 71% in BCS patients

Read more

Summary

Introduction

Breast cancer (ICD 10: C50) is the second most common cancer among both sexes worldwide (Globocon, 2012). In 2002, Whelan et al, reported the 5-year results of their trial in which they compared whole breast radiotherapy dose of 50 Gy given in 25 fractions over 35 days versus a hypofractionated schedule of 42.5 Gy given in 16 fractions over a period of 22 days, after breast-conserving surgery in women with axillary lymph node negative breast cancer. After a median follow up of 6 years; the rate of loco-regional tumour recurrence at 5 years was 2·2% in the 40 Gy group and 3·3% in the 50 Gy group This trial established that a hypofractionated schedule of 40 Gy in 15 fractions was equivalent to the standard schedule of 50 Gy in 25 fractions in terms of rates of tumour relapse and late adverse effects.

Materials and Methods
DQG ODWHUDO UG RI WKH FODYLFOH LQFOXGLQJ WKH FRUDFRLG
Most of the patients were ER positive in both BCS
END RT
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call